LYMPHOID NEOPLASIA Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 1 T-cell killing
暂无分享,去创建一个
P. Leone | V. Racanelli | M. Frassanito | S. Cicco | S. Battaglia | P. Ditonno | V. Re | S. Berardi | F. Dammacco | Roberto Ria | Angelo Vacca
[1] P. L. Bergsagel,et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. , 2014, Blood.
[2] F. Dammacco,et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.
[3] O. Joffre,et al. Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.
[4] Je-Jung Lee,et al. Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? , 2012, Clinical & developmental immunology.
[5] P. L. Bergsagel,et al. CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment , 2011, The Journal of Immunology.
[6] H. Ueno,et al. Dendritic cells and immunity against cancer , 2011, Journal of internal medicine.
[7] Ash A. Alizadeh,et al. Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.
[8] Silvano Sozzani,et al. Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.
[9] F. Dammacco,et al. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. , 2010, Blood.
[10] Hongbo Zhao,et al. Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. , 2007, Cellular signalling.
[11] F. Dammacco,et al. Bone Marrow of Persistently Hepatitis C Virus-Infected Individuals Accumulates Memory CD8+ T Cells Specific for Current and Historical Viral Antigens: A Study in Patients with Benign Hematological Disorders1 , 2007, The Journal of Immunology.
[12] S. Jagannath,et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.
[13] H. Johnsen,et al. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma , 2006, Clinical and experimental immunology.
[14] W. Janssen,et al. Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte , 2005, Cell.
[15] R. Pope,et al. The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis , 2005, Arthritis research & therapy.
[16] H. Johnsen,et al. Impaired circulating myeloid DCs from myeloma patients. , 2004, Cytotherapy.
[17] M. Dhodapkar,et al. Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy , 2003, The Journal of experimental medicine.
[18] M. Feuerer,et al. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. , 2003, Trends in molecular medicine.
[19] M. Feuerer,et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen , 2003, Nature Medicine.
[20] M. Dhodapkar,et al. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Baccarani,et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.
[22] D. Joshua,et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. , 2001, Blood.
[23] P. Srivastava,et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.
[24] Dongshu Chen,et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. , 1999, Blood.
[25] H. Goldschmidt,et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors , 1997, British journal of haematology.
[26] P. Doherty,et al. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. , 1997, Journal of immunology.
[27] Patrizia Agostinis,et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. , 2010, Biochimica et biophysica acta.
[28] M. Pérez‐Andrés,et al. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. , 2008, The oncologist.
[29] A. Palucka,et al. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance , 2008, Cell Death and Differentiation.
[30] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[31] Laurence Zitvogel,et al. Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.
[32] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.